Climb Bio (CLYM) Assets (2020 - 2026)
Climb Bio's (CLYM) quarterly Assets came in at $152.4 million in Q1 2026, down 24.09% YoY from $200.7 million in Q1 2025, and down 9.16% on a QoQ basis from $167.7 million in Q4 2025.
Climb Bio (CLYM) Assets (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Assets data on file, last reported at $152.4 million in Q1 2026.
- Quarterly Assets fell 24.09% year-over-year to $152.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.4 million (down 24.09% YoY) and the FY2025 annual result came in at $167.7 million, down 22.77% from the prior year.
- Assets eased to $152.4 million in Q1 2026, from $167.7 million in the prior quarter.
- In the past five years, Assets ranged from a high of $226.0 million in Q2 2024 to a low of $109.3 million in Q1 2024.
- A 5-year average of $160.0 million and a median of $152.4 million in 2026 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets dropped 24.83% — and 2024, when it jumped 97.1%.
- Tracing CLYM's Assets over 5 years: stood at $135.0 million in 2022, then dropped by 18.17% to $110.5 million in 2023, then jumped by 96.6% to $217.2 million in 2024, then dropped by 22.77% to $167.7 million in 2025, then decreased by 9.16% to $152.4 million in 2026.
- The last three Assets figures came in at $152.4 million (Q1 2026), $167.7 million (Q4 2025), and $182.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 246.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 246.29 Mn |
| Mar 31, 2026 | 152.37 Mn |
| Dec 31, 2025 | 167.74 Mn |
| Sep 30, 2025 | 182.30 Mn |
| Jun 30, 2025 | 192.39 Mn |
| Mar 31, 2025 | 200.74 Mn |
| Dec 31, 2024 | 217.19 Mn |
| Sep 30, 2024 | 222.20 Mn |
| Jun 30, 2024 | 226.02 Mn |
| Mar 31, 2024 | 109.33 Mn |
| Dec 31, 2023 | 110.47 Mn |
| Sep 30, 2023 | 112.74 Mn |
| Jun 30, 2023 | 116.27 Mn |
| Mar 31, 2023 | 122.09 Mn |
| Dec 31, 2022 | 134.99 Mn |
| Sep 30, 2022 | 140.86 Mn |
| Jun 30, 2022 | 150.11 Mn |
| Mar 31, 2022 | 162.42 Mn |
| Dec 31, 2021 | 173.24 Mn |
| Sep 30, 2021 | 182.25 Mn |